Literature DB >> 23319096

Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?

Kush Agrawal, Deepak L Bhatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23319096     DOI： 10.1038/nrcardio.2012.199

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

Review 1.  The evolution of antiplatelet therapy in cardiovascular disease.

Authors:  Omair Yousuf; Deepak L Bhatt
Journal:  Nat Rev Cardiol       Date:  2011-07-12       Impact factor: 32.419

2.  Intensifying platelet inhibition--navigating between Scylla and Charybdis.

Authors:  Deepak L Bhatt
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

3.  Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.

Authors:  Antonius A C M Heestermans; Jochem W van Werkum; Dirk Taubert; Toine H Seesing; Nicolas von Beckerath; Christian M Hackeng; Edgar Schömig; F W A Verheugt; Jurriën M ten Berg
Journal:  Thromb Res       Date:  2008-05-01       Impact factor: 3.944

4.  Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Authors:  Sergio Leonardi; Kenneth W Mahaffey; Harvey D White; C Michael Gibson; Gregg W Stone; Gabriel W Steg; Christian W Hamm; Matthew J Price; Meredith Todd; Markus Dietrich; Dianne Gallup; Tiepu Liu; Simona Skerjanec; Robert A Harrington; Deepak L Bhatt
Journal:  Am Heart J       Date:  2012-05       Impact factor: 4.749

5.  Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Authors:  Dimitrios Alexopoulos; Ioanna Xanthopoulou; Vassilios Gkizas; George Kassimis; Konstantinos C Theodoropoulos; George Makris; Nikolaos Koutsogiannis; Anastasia Damelou; Grigorios Tsigkas; Periklis Davlouros; George Hahalis
Journal:  Circ Cardiovasc Interv       Date:  2012-11-20       Impact factor: 6.546

6.  Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.

Authors:  Philippe Gabriel Steg; Stefan James; Robert A Harrington; Diego Ardissino; Richard C Becker; Christopher P Cannon; Håkan Emanuelsson; Ariel Finkelstein; Steen Husted; Hugo Katus; Jan Kilhamn; Sylvia Olofsson; Robert F Storey; W Douglas Weaver; Lars Wallentin
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

7.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

8.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

9.  Intravenous platelet blockade with cangrelor during PCI.

Authors:  Deepak L Bhatt; A Michael Lincoff; C Michael Gibson; Gregg W Stone; Steven McNulty; Gilles Montalescot; Neal S Kleiman; Shaun G Goodman; Harvey D White; Kenneth W Mahaffey; Charles V Pollack; Steven V Manoukian; Petr Widimsky; Derek P Chew; Fernando Cura; Ivan Manukov; Frantisek Tousek; M Zubair Jafar; Jaspal Arneja; Simona Skerjanec; Robert A Harrington
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

Authors:  Gilles Montalescot; Stephen D Wiviott; Eugene Braunwald; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Elliott M Antman
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321
  10 in total
  2 in total

1.  Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials.

Authors:  Yong Tang; Ya-Chen Zhang; Yu Chen; Yin Xiang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.

Authors:  Leonardo De Luca; Paolo Calabrò; Fabio Chirillo; Cristina Rolfo; Alberto Menozzi; Piera Capranzano; Maurizio Menichelli; Elisa Nicolini; Ciro Mauro; Carlo Trani; Francesco Versaci; Fabrizio Tomai; Giuseppe Musumeci; Carlo Di Mario; Martino Pepe; Sergio Berti; Carlo Cernetti; Plinio Cirillo; Diego Maffeo; Giuseppe Talanas; Marco Ferlini; Marco Contarini; Valerio Lanzilotti; Marino Scherillo; Giuseppe Tarantini; Simone Muraglia; Roberta Rossini; Leonardo Bolognese
Journal:  Clin Cardiol       Date:  2022-06-22       Impact factor: 3.287
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.